Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZARNESTRA, tipifarnib, R115777 · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| ZARNESTRA, tipifarnib, R115777 | DRUG | - |
Inclusion Criteria: * Locally advanced, inoperable loco-regionally-recurrent, or metastatic breast cancer * Estrogen and/or progesterone positive disease * Progression of disease after antiestrogen therapy * Measurable disease * Postmenopausal * Eastern Cooperative Oncology Group (ECOG) performance...
ZARNESTRA, also known as tipifarnib or R115777, is an investigational small molecule being studied for the treatment of acute myeloid leukemia, breast cancer, and myelodysplastic syndrome. It is in Phase 2 clinical development and is not yet approved by the FDA.
ZARNESTRA (tipifarnib) is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 2 clinical trials for oncology indications.
ZARNESTRA (tipifarnib) is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Clinical trials have been completed for acute myeloid leukemia, breast cancer, and myelodysplastic syndrome.
ZARNESTRA (tipifarnib) has completed three Phase 2 trials: NCT00048503 in acute myeloid leukemia, NCT00050141 in advanced breast cancer, and NCT00050154 in high-risk myelodysplastic syndrome. These trials are completed, and no active trials are currently listed.
Yes, ZARNESTRA is the brand name for tipifarnib, which is also known by the research code R115777. These names refer to the same investigational small molecule drug being developed by Johnson & Johnson for oncology indications.